Mortality of patients excluded from the Danish Verapamil Infarction Trail II. The DAVIT-II Study Group.
The 18 month mortality rate in 2180 patients excluded from the Danish Verapamil Infarction Trail II (DAVIT II) was 25.6%. In non-consenters (n = 368) this was 15.0% compared with 13.85 in 897 placebo-treated patients (hazard ratio 1.09 [P = 0.60] when adjusting for sex and age). The increased mortality rate in excluded patients is attributed to heart failure (45.8%) and other severe diseases (38.9%).
Madsen
J K
JK
Department of Cardiology, Hvidovre Hospital, Copenhagen, Denmark.
Hansen
J F
JF
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002985:Clinical Protocols; D002986:Clinical Trials as Topic / Q000379:methods; D003718:Denmark; D005260:Female; D006331:Heart Diseases / Q000150:complications*; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009026:Mortality; D009203:Myocardial Infarction / Q000150:complications* / Q000188:drug therapy; D016016:Proportional Hazards Models; D014700:Verapamil / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers; D014700:Verapamil